Please ensure Javascript is enabled for purposes of website accessibility

Why GW Pharmaceuticals Stock Rose 10% in January

By George Budwell – Feb 5, 2020 at 10:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company has been one of the few bright spots in the struggling cannabis industry.

What happened

After an underwhelming 2019, shares of GW Pharmaceuticals (GWPH) perked up nicely in January, with the drugmaker's stock jumping 10% for the month, according to data from S&P Global Market Intelligence. The gain last month came in response to the company's preliminary fourth-quarter and full-year results released on Jan. 12. 

The major headline is the rapidly growing sales of the company's cannabis-based epilepsy medicine Epidiolex. During its first full year of sales as a treatment for two rare but potentially deadly forms of childhood epilepsy, Epidiolex hauled in an astounding $296 million. 

Marijuana leaf

Image source: Getty Images.

So what

Investors cheered these strong financial results for two reasons. First, there was some concern among Wall Street analysts about Epidiolex's commercial viability ahead of its official launch. The concern stemmed from its rather high price and the fact that there are far cheaper alternatives already on the market. GW proved the naysayers wrong by transforming this cannabis-based medicine into an absolute commercial powerhouse. Second, GW has been one of the only unmitigated successes in the closely watched cannabis space. While other cannabis stocks floundered on the commercial front last year, GW actually exceeded expectations for the full year.  

Now what

Can GW's stock keep marching higher? Wall Street presently has an average price target on the shares of $201.53, implying a staggering upside potential of approximately 72% from current levels. To get to this next level, however, GW will have to continue to deliver in both the clinic and the marketplace.

Luckily, the drugmaker has been able to score high marks on both of these key fronts over the past year. That doesn't mean that GW's winning streak is guaranteed to continue in 2020, but there's also no obvious reason to doubt the company at this point. As a result, investors may want to think about adding this top growth stock to their portfolio soon. 


George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

GW Pharmaceuticals plc Stock Quote
GW Pharmaceuticals plc

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.